​

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RYTM Stock Forecast

Rhythm Pharmaceuticals (RYTM) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $135.00, with a high of $157.00 and a low of $110.00. This represents a 14.87% increase from the last price of $117.52.

- $40 $80 $120 $160 $200 High: $157 Avg: $135 Low: $110 Last Closed Price: $117.52

RYTM Stock Rating

Rhythm Pharmaceuticals stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 17 Strong Sell Sell Hold Buy Strong Buy

RYTM Price Target Upside V Benchmarks

TypeNameUpside
StockRhythm Pharmaceuticals14.87%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3714
Avg Price Target$149.33$138.29$114.79
Last Closing Price$117.52$117.52$117.52
Upside/Downside27.07%17.67%-2.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 253111--15
Nov, 25410---14
Oct, 25410---14
Sep, 25410---14
Aug, 25410---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 12, 2025Goldman Sachs$157.00$117.5233.59%33.59%
Dec 12, 2025Whitney IjemCanaccord Genuity$141.00$117.5219.98%19.98%
Dec 11, 2025Morgan Stanley$150.00$117.5227.64%27.64%
Oct 17, 2025Corinne JohnsonGoldman Sachs$139.00$111.1825.02%18.28%
Oct 16, 2025Morgan Stanley$129.00$109.3517.97%9.77%
Sep 29, 2025Raghuram SelvarajuH.C. Wainwright$110.00$99.1610.93%-6.40%
Sep 25, 2025Jonathan WollebenJMP Securities$142.00$98.7643.78%20.83%
Aug 05, 2025Morgan Stanley$109.00$88.5723.07%-7.25%
Jul 10, 2025Leland GershellOppenheimer$110.00$89.0423.54%-6.40%
Jul 10, 2025Corinne JohnsonGoldman Sachs$97.00$89.048.94%-17.46%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 12, 2025Goldman SachsBuyBuyhold
Dec 12, 2025CitigroupOutperformOutperformhold
Dec 11, 2025Morgan StanleyOverweightOverweighthold
Dec 11, 2025Cowen & Co.BuyBuyhold
Nov 25, 2025CitigroupOutperformBuyinitialise
Nov 05, 2025OppenheimerOutperformPerformdowngrade
Oct 17, 2025Goldman SachsBuyBuyhold
Oct 16, 2025Morgan StanleyOverweightOverweighthold
Sep 29, 2025H.C. WainwrightBuyBuyhold
Sep 25, 2025CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.96$-1.37$-3.51$-3.20$-4.34----
Avg Forecast$-3.02$-1.45$-3.53$-3.20$-4.12$-2.46$-0.75$2.25$6.28
High Forecast$-2.67$-1.28$-3.23$-3.16$-3.82$-1.98$0.06$2.74$7.69
Low Forecast$-3.55$-1.70$-4.09$-3.27$-4.39$-2.79$-2.04$1.22$5.49
Surprise %-1.99%-5.52%-0.57%-5.34%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$3.15M$23.64M$77.43M$130.13M----
Avg Forecast$52.97K$3.03M$21.41M$78.80M$126.00M$181.85M$333.83M$602.63M$970.38M
High Forecast$60.18K$3.44M$23.99M$80.69M$127.08M$208.91M$333.83M$602.63M$1.14B
Low Forecast$48.25K$2.76M$20.00M$77.29M$125.06M$164.87M$333.83M$602.63M$876.95M
Surprise %-4.19%10.43%-1.75%3.27%----

Net Income Forecast

$-300M $-150M $0 $150M $300M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-130.73M$-68.01M$-183.08M$-184.68M$-264.57M----
Avg Forecast$-174.03M$-83.43M$-203.78M$-184.68M$-236.88M$-137.49M$-42.97M$114.18M$362.02M
High Forecast$-153.88M$-73.77M$-186.37M$-182.31M$-220.43M$-113.92M$3.61M$158.06M$443.67M
Low Forecast$-204.80M$-98.19M$-235.71M$-188.66M$-253.33M$-161.06M$-117.89M$70.31M$316.71M
Surprise %-24.88%-18.49%-10.16%-11.69%----

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals stock a buy?

Rhythm Pharmaceuticals stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rhythm Pharmaceuticals is a favorable investment for most analysts.

What is Rhythm Pharmaceuticals's price target?

Rhythm Pharmaceuticals's price target, set by 17 Wall Street analysts, averages $135 over the next 12 months. The price target range spans from $110 at the low end to $157 at the high end, suggesting a potential 14.87% change from the previous closing price of $117.52.

How does Rhythm Pharmaceuticals stock forecast compare to its benchmarks?

Rhythm Pharmaceuticals's stock forecast shows a 14.87% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rhythm Pharmaceuticals over the past three months?

  • December 2025: 20.00% Strong Buy, 73.33% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Rhythm Pharmaceuticals’s EPS forecast?

Rhythm Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.46, marking a -43.32% decrease from the reported $-4.34 in 2024. Estimates for the following years are $-0.75 in 2026, $2.25 in 2027, and $6.28 in 2028.

What is Rhythm Pharmaceuticals’s revenue forecast?

Rhythm Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $181.85M, reflecting a 39.75% increase from the reported $130.13M in 2024. The forecast for 2026 is $333.83M, followed by $602.63M for 2027, and $970.38M for 2028.

What is Rhythm Pharmaceuticals’s net income forecast?

Rhythm Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-137M, representing a -48.03% decrease from the reported $-265M in 2024. Projections indicate $-42.973M in 2026, $114.18M in 2027, and $362.02M in 2028.